Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Stocks Continue Slide

Genomics stocks continue to lead the biotech sectors on a downward slide Wednesday morning.

Celera Genomics dropped another 4.7 percent by mid-day after shedding 7 percent Tuesday.Incyte Genomics slipped another 4 percent following a 4.2 percent decline the day before. And the market chipped an additional 5.4 percent of Affymetrix stock following a previous day decline of 5.1 percent.

“The genomic stocks,” said AG Edwards analyst Alexander Hittle, “are like biotech stocks on steroids.” So when biotech and pharma slip, genomics dive. Part of the dip, say analysts, is standard market animal forces. The sector has done really well through the summer, and investors are taking their profits and rebalancing their portfolios.

Genomic stocks are also being hit especially hard because “there are at least 10 companies for whom their six-month lockups will expire from mid-September to early November,” said Winton Gibbons, genomic sector analyst at William Blair.

Add to that, said Gibbons, at least half dozen genomic platform and bioinformatic initial public offerings in the same time frame and you have a market glut of genomic shares.

“The presidential politics are also possibly playing a role,” said Gibbons, with investors having the long weekend to take in the rhetoric on pharmaceutical pricing.

Despite all these factors, Gibbons thinks investors are still excited about the sector. “You’ve got at least four investor conferences coming up between now and the first week of October,” he said. “There’s still demand out there.”
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.